Safety and Outcome Measures of First-in-Human Intraperitoneal α Radioimmunotherapy With 212Pb-TCMC-Trastuzumab

Autor: J. Michael Straughn, Ronald D. Alvarez, Tania A. Rozgaja, E. Banaga, Julien Torgue, Michael C. Dobelbower, Ruby F. Meredith, Andrew M. Lowy, Patty Bunch
Jazyk: angličtina
Rok vydání: 2016
Předmět:
Cancer Research
Pathology
medicine.medical_treatment
intraperitoneal
Gastroenterology
030218 nuclear medicine & medical imaging
Pb-212-radioimmunotherapy
0302 clinical medicine
Carcinoembryonic antigen
Antineoplastic Agents
Immunological
Trastuzumab
Isothiocyanates
Outcome Assessment
Health Care
Medicine
Peritoneal Neoplasms
Aged
80 and over
Ovarian Neoplasms
biology
Lead Radioisotopes
Middle Aged
Prognosis
3. Good health
Original Articles: Experimental Therapeutics
Survival Rate
Oncology
030220 oncology & carcinogenesis
Radioimmunotherapy
Female
medicine.drug
medicine.medical_specialty
03 medical and health sciences
Internal medicine
cancer
ovarian
Humans
Mesothelin
Serum amyloid A
Survival rate
Tumor marker
Aged
business.industry
medicine.disease
tumor marker
biology.protein
Neoplasm Recurrence
Local
business
Ovarian cancer
Follow-Up Studies
Zdroj: American Journal of Clinical Oncology
ISSN: 1537-453X
0277-3732
Popis: One-year monitoring of patients receiving intraperitoneal (IP) 212Pb-TCMC-trastuzumab to provide long-term safety and outcome data. A secondary objective was to study 7 tumor markers for correlation with outcome. Eighteen patients with relapsed intra-abdominal human epidermal growth factor receptor-2 expressing peritoneal metastases were treated with a single IP infusion of 212Pb-TCMC-trastuzumab, delivered
Databáze: OpenAIRE
Externí odkaz: